An Observational Study to Evaluate Disease Control, Safety and Immunological Changes in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Transferred From Previous Treatment With Natalizumab to Fingolimod.
Phase of Trial: Phase II
Latest Information Update: 23 Sep 2016
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 13 Sep 2016 Status changed from recruiting to completed.
- 01 Nov 2014 New trial record